Literature DB >> 27553918

Prospective Evaluation of Passive Expansion of Partially Dilated Transjugular Intrahepatic Portosystemic Shunt Stent Grafts-A Three-Dimensional Sonography Study.

Claus Christian Pieper1, Christian Jansen2, Carsten Meyer1, Jennifer Nadal3, Jennifer Lehmann2, Hans Heinz Schild1, Jonel Trebicka2, Daniel Thomas4.   

Abstract

PURPOSE: To prospectively investigate early expansion kinetics of underdilated self-expanding stent grafts used for transjugular intrahepatic portosystemic shunt (TIPS) creation.
MATERIALS AND METHODS: Twenty patients (7 female; mean age 66 y; range, 31-80 y) with liver cirrhosis undergoing TIPS creation for variceal bleeding (n = 5), refractory ascites (n = 14), or both (n = 1) with underdilation of 10-mm stent grafts received two-dimensional (2-D) and three-dimensional (3-D) ultrasound (US) examinations immediately after TIPS creation and 1 and 6 weeks later. Orthogonal views of the TIPS within the parenchymal tract were reconstructed from 3-D volume data sets acquired in longitudinal orientation of the stent. 2-D images and reconstructed 3-D images were used for blinded diameter measurements. Measurement technique was validated with intrainterventional plain radiographs with a sizing catheter as the gold standard. Diameter changes over time and interrelations with patient characteristics (null hypothesis: no expansion, no interrelation) were analyzed using a general linear model for repeated measures.
RESULTS: After dilation to 8-mm diameter, 2-D and 3-D measurements showed stent recoil (mean diameter 7.7 mm ± 0.21 and 7.6 mm ± 0.17, respectively). Diameter increased significantly from initial measurements to measurements at 1 and 6 weeks (2-D, 8.8 mm ± 0.24 and 9.4 mm ± 0.15, both P < .001; 3-D, 8.7 mm ± 0.27 and 9.4 mm ± 0.11, both P < .001). Validation measurements showed no significant differences between 2-D or 3-D US and gold standard. There were no statistically significant associations between stent expansion and clinical parameters (sex, P = .78; age, P = .82; etiology/grade of cirrhosis, P = .99; indication for TIPS, P = .78, liver stiffness, P = .70).
CONCLUSIONS: Underdilated self-expanding stent grafts used for TIPS creation significantly expand within first 6 weeks after intervention. These changes can be noninvasively monitored using 3-D US.
Copyright © 2016 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27553918     DOI: 10.1016/j.jvir.2016.06.023

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  9 in total

Review 1.  Where does TIPS fit in the management of patients with cirrhosis?

Authors:  Juan Carlos García-Pagán; Saad Saffo; Mattias Mandorfer; Guadalupe Garcia-Tsao
Journal:  JHEP Rep       Date:  2020-05-23

2.  Variable efficacy of TIPSS in the management of ectopic variceal bleeding: a multicentre retrospective study.

Authors:  Rosalie C Oey; Koos de Wit; Adriaan Moelker; Tugce Atalik; Otto M van Delden; Geert Maleux; Nicole S Erler; R Bart Takkenberg; Robert A de Man; Frederik Nevens; Henk R van Buuren
Journal:  Aliment Pharmacol Ther       Date:  2018-08-22       Impact factor: 8.171

3.  Ascites control by TIPS is more successful in patients with a lower paracentesis frequency and is associated with improved survival.

Authors:  Felix Piecha; Ulf K Radunski; Ann-Kathrin Ozga; David Steins; Andreas Drolz; Thomas Horvatits; Clemens Spink; Harald Ittrich; Daniel Benten; Ansgar W Lohse; Christoph Sinning; Johannes Kluwe
Journal:  JHEP Rep       Date:  2019-05-10

4.  Controlled underdilation using novel VIATORR® controlled expansion stents improves survival after transjugular intrahepatic portosystemic shunt implantation.

Authors:  Michael Praktiknjo; Jasmin Abu-Omar; Johannes Chang; Daniel Thomas; Christian Jansen; Patrick Kupczyk; Filippo Schepis; Juan Carlos Garcia-Pagan; Manuela Merli; Carsten Meyer; Christian P Strassburg; Claus C Pieper; Jonel Trebicka
Journal:  JHEP Rep       Date:  2021-03-03

5.  Cranial stent position is independently associated with the development of TIPS dysfunction.

Authors:  Carsten Meyer; Alba Maria Paar Pérez; Johannes Chang; Alois Martin Sprinkart; Nina Böhling; Andreas Minh Luu; Daniel Kütting; Christian Jansen; Julian Luetkens; Leon Marcel Bischoff; Ulrike Attenberger; Christian P Strassburg; Jonel Trebicka; Karsten Wolter; Michael Praktiknjo
Journal:  Sci Rep       Date:  2022-03-03       Impact factor: 4.379

6.  Potential Benefits of Underdilation of 8-mm Covered Stent in Transjugular Intrahepatic Portosystemic Shunt Creation.

Authors:  Jiacheng Liu; Jinqiang Ma; Chen Zhou; Chongtu Yang; Songjiang Huang; Qin Shi; Bin Xiong
Journal:  Clin Transl Gastroenterol       Date:  2021-06-18       Impact factor: 4.488

Review 7.  Unsolved Questions in Salvage TIPSS: Practical Modalities for Placement, Alternative Therapeutics, and Long-Term Outcomes.

Authors:  Charlotte Bouzbib; Philippe Sultanik; Dominique Thabut; Marika Rudler
Journal:  Can J Gastroenterol Hepatol       Date:  2019-04-01

Review 8.  North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension.

Authors:  Justin R Boike; Bartley G Thornburg; Sumeet K Asrani; Michael B Fallon; Brett E Fortune; Manhal J Izzy; Elizabeth C Verna; Juan G Abraldes; Andrew S Allegretti; Jasmohan S Bajaj; Scott W Biggins; Michael D Darcy; Maryjane A Farr; Khashayar Farsad; Guadalupe Garcia-Tsao; Shelley A Hall; Caroline C Jadlowiec; Michael J Krowka; Jeanne Laberge; Edward W Lee; David C Mulligan; Mitra K Nadim; Patrick G Northup; Riad Salem; Joseph J Shatzel; Cathryn J Shaw; Douglas A Simonetto; Jonathan Susman; K Pallav Kolli; Lisa B VanWagner
Journal:  Clin Gastroenterol Hepatol       Date:  2021-07-15       Impact factor: 13.576

9.  History of Hepatic Encephalopathy Is Not a Contraindication to Transjugular Intrahepatic Portosystemic Shunt Placement for Refractory Ascites.

Authors:  Sammy Saab; Matthew Zhao; Ishan Asokan; Jung Jun Yum; Edward Wolfgang Lee
Journal:  Clin Transl Gastroenterol       Date:  2021-08-01       Impact factor: 4.488

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.